Tibet Aim Pharm

Tibet Aim Pharm Interest Coverage

The Interest Coverage Ratio of Tibet Aim Pharm (002826.SZ) as of Nov 19, 2026 is 12.95. In the previous year, Interest Coverage Ratio was 6.06 — a change of 113.67% (higher).

Interest Coverage

12.95

YoY

113.67%

Last updated:

Interest Coverage Ratio of Tibet Aim Pharm is 2024 12.95 . Interest Coverage Ratio of Tibet Aim Pharm was 2023 6.06 . It decreases by 113.67% higher compared to the previous year.

The Tibet Aim Pharm Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
21.70 CNY
Jan 1, 2018
10.74 CNY
Jan 1, 2019
47.70 CNY
Jan 1, 2020
431.26 CNY
Jan 1, 2021
23.41 CNY
Jan 1, 2022
17.86 CNY
Jan 1, 2023
6.06 CNY
Jan 1, 2024
12.95 CNY
The Tibet Aim Pharm Interest Coverage history
YEARInterest CoverageYoY
12.95+113.67%
6.06-66.07%
17.86-23.72%
23.41-94.57%
431.26+804.05%
47.70+344.06%
10.74-50.50%
21.70+51.88%
14.29-78.00%
64.94+116.72%
29.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Aim Pharm Stock analysis

What does Tibet Aim Pharm do? Tibet Aim Pharm., Inc. generates revenue through the research, development, production, and sale of chemical drugs and Chinese medicines. The company's self-manufacturing medicine portfolio features miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, and domperidone tablets. Third-party medicine offerings include gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, and carbetocin injection. Domestic and overseas markets are the primary sales channels for these products, with the company distributing its medicines across both segments. The firm's self-manufacturing medicines are sold to domestic healthcare providers and consumers, while third-party medicine products are distributed through partnerships with other pharmaceutical entities. The company's product mix caters to various therapeutic areas, including gastrointestinal, cardiovascular, and pediatric treatments. Revenue streams are derived from direct sales of its proprietary drugs and third-party agreements for distribution. Tibet Aim Pharm., Inc. serves the domestic Chinese market and international markets with its chemical drugs and Chinese medicines. The company's product range targets healthcare institutions, pharmacies, and end consumers for self-manufacturing medicines, while third-party medicine products are supplied to distributors and healthcare facilities. The business model relies on manufacturing and distributing a diverse portfolio of pharmaceutical products to meet market demand. Tibet Aim Pharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Aim Pharm stock

Interest Coverage Ratio of Tibet Aim Pharm is 12.95 in 2024.

Interest Coverage Ratio of Tibet Aim Pharm changed from 6.06 to 12.95, representing a 113.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Tibet Aim Pharm since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Tibet Aim Pharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Tibet Aim Pharm

All Key Metrics — Tibet Aim Pharm